Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab
暂无分享,去创建一个
L. Stenberg | S. Strand | T. Ohlsson | D. Goldenberg | C. Hindorf | O. Lindén | E. Cavallin-ståhl | W. Wegener | J. Tennvall | H. Horne
[1] L. Gordon,et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Zelenetz,et al. The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy , 2004, Clinical Cancer Research.
[3] G Sgouros,et al. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] J. Cyster,et al. Tuning antigen receptor signaling by CD22: integrating cues from antigens and the microenvironment. , 1997, Immunity.
[5] L. Gordon,et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Richard L Wahl,et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. , 2005, The New England journal of medicine.
[7] D. Rizzieri,et al. Radioimmunotherapy for Non-Hodgkin's Lymphoma. , 2005, Clinical medicine & research.
[8] T Ohlsson,et al. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] G. Denardo,et al. Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[10] L. Stenberg,et al. Change in tumor-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] J. Vose,et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Juweid,et al. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22 , 1997, Cancer Immunology, Immunotherapy.
[13] Herbert Malamud,et al. MIRD Primer for Absorbed Dose Calculations , 1989 .
[14] D. Goldenberg,et al. Radioimmunotherapy of non-Hodgkin's lymphoma revisited. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Leonard,et al. CD22-directed monoclonal antibody therapy for lymphoma. , 2003, Seminars in oncology.
[17] J. Leonard,et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] A S Dion,et al. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. , 1995, Molecular immunology.
[19] J. Leonard,et al. Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma , 2004, Clinical Cancer Research.
[20] J. Schlom,et al. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. , 1990, Journal of the National Cancer Institute.
[21] George Sgouros,et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy , 2002, Cancer.
[22] A. Timothy,et al. Low dose palliative radiotherapy in low grade non-Hodgkin's lymphoma. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[23] G. Griffiths,et al. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[24] J. Armitage,et al. Phase I/II Trial of Multiple Dose 131Iodine-MAb LL2 (CD22) in Patients with Recurrent Non-Hodgkin's Lymphoma , 2000, Leukemia & lymphoma.
[25] M. Kaminski,et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. , 2000, Blood.
[26] L. Gordon,et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] L. Gordon,et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. , 2002, Blood.
[28] J. McGahan,et al. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. , 1998, Cancer biotherapy & radiopharmaceuticals.
[29] A. Alavi,et al. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[30] D. Goldenberg,et al. Internalization and intracellular processing of an anti B‐cell lymphoma monoclonal antibody, ll2 , 1994, International journal of cancer.
[31] J. Vose,et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] D. Goldenberg,et al. Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2 , 1993, Cancer Immunology, Immunotherapy.
[33] J. O’Donoghue. Dosimetric Principles of Targeted Radiotherapy , 2000 .
[34] J. Leonard,et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] I. Bernstein,et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. , 1993, The New England journal of medicine.